Iroko Pharmaceuticals receives patent for osteoarthritis drug VIVLODEX

Iroko Pharmaceuticals LLC, a company focused on advancing the science of analgesia, recently received a patent for VIVLODEX (meloxicam) capsules 5 mg and 10 mg.
The drug, which is the first Food and Drug Administration-approved, low-dose SoluMatri meloxicam, was created to manage osteoarthritis pain through once daily doses. VIVLODEX is a non-steroids anti-inflammatory drug.
"This new patent reflects our fruitful collaboration with our partner, iCeutica, and the high quality work of our combined team," Iroko Pharmaceuticals Chairman Osagie Imasogie said.
The patent was issued by the U.S. Patent and Trademark Office and will be listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations publication. Also known as the Orange Book, this publication includes all the drugs the FDA has approved, as well as patent information for the drugs.
Iroko’s patent for VIVLODEX will not expire before 2033.